Avanos (AVNS) Medical announced the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, a privately held company based in Raleigh, NC. The divested portfolio includes the TriVisc and GenVisc 850 injection products, which are indicated for the treatment of osteoarthritis pain in the knee. These injectable HA therapies are designed to help patients manage OA symptoms and improve joint function. With this announcement, ownership of Avanos’ HA product line has officially transferred to CMM. Avanos will provide transition support through the end of 2025 to ensure uninterrupted service and support for customers, partners, and patients.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVNS: